New shot cuts migraine days by half in chinese trial
NCT ID NCT05458011
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called fremanezumab, given as a shot under the skin, to prevent migraines in 365 Chinese adults. Participants received either monthly or quarterly injections or a placebo for 12 weeks, followed by an open-label period. The main goal was to see if the drug reduced the number of migraine days per month. The trial was completed and showed that fremanezumab helped lower migraine frequency.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Teva Investigational Site 88001
Beijing, 100853, China
-
Teva Investigational Site 88003
Chengdu, 610041, China
-
Teva Investigational Site 88004
Beijing, 100044, China
-
Teva Investigational Site 88005
Luoyang, 4710039, China
-
Teva Investigational Site 88006
Wuhan, 430071, China
-
Teva Investigational Site 88008
Changchun, 130021, China
-
Teva Investigational Site 88009
Changchun, 130041, China
-
Teva Investigational Site 88010
Lianyungang, 222002, China
-
Teva Investigational Site 88011
Shijiazhuang, 50073, China
-
Teva Investigational Site 88012
Wuhan, 430030, China
-
Teva Investigational Site 88013
Guiyang, 550004, China
-
Teva Investigational Site 88015
Suzhou, 215004, China
-
Teva Investigational Site 88016
Shenyang, 110016, China
-
Teva Investigational Site 88017
Wenzhou, 325000, China
-
Teva Investigational Site 88019
Fuzhou, 350001, China
-
Teva Investigational Site 88020
Guangzhou, 510260, China
-
Teva Investigational Site 88021
Shanghaishi, 200040, China
-
Teva Investigational Site 88022
Changsha Shi, 410008, China
-
Teva Investigational Site 88023
Tianjin, 300120, China
-
Teva Investigational Site 88024
Tianjin, 300052, China
-
Teva Investigational Site 88025
Shanghaishi, 200120, China
-
Teva Investigational Site 88026
Harbin, 150001, China
-
Teva Investigational Site 88028
Baotou Shi, 014060, China
-
Teva Investigational Site 88029
Chongqing, 400700, China
-
Teva Investigational Site 88030
Changsha Shi, 410013, China
-
Teva Investigational Site 88031
Zhanjiang, 524008, China
-
Teva Investigational Site 88032
Xining, 810007, China
-
Teva Investigational Site 88033
Rizhao, 276800, China
-
Teva Investigational Site 88034
Zhengzhou, 450003, China